Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.35    -0.10 (-0.61%)
Bid:
16.30
Ask:
16.45
Spread: 0.15 (0.92%)
Market Cap: £131.05m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Trading Update

24 Jun 2013 07:00

RNS Number : 6463H
Allocate Software PLC
24 June 2013
 



24 June 2013

 

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

 

Full Year Trading Update

 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2013. The Company's audited results will be announced in the week commencing 22 July 2013.

 

Overview

 

Allocate delivered a very strong second half performance with full year results in line with market expectations for both revenue and EBITA. The Company's cash performance has materially exceeded analysts' expectations due to the continuing transition in the Company's business model to one based more on recurring revenues and due to improvements in working capital.

 

Business

 

The Healthcare business achieved another successful year securing a significant number of agreements for both new products and new customers.

 

UK Healthcare bookings are ahead of revenue because the number of recurring orders secured has been higher than anticipated. The financial effect of this is that cash, deferred revenue and contracted, unbilled orders in hand are higher than anticipated. As a result, this will increase the visibility and predictability of future years' revenue streams.

 

The number of new HealthRoster customers secured by the Company was slightly fewer than the previous financial year but met management's expectations for the second half of the current year. Several of the new customers secured were competitor displacements and HealthRoster renewals continued at the previously recorded 100% renewal rate.

 

The Allocate Cloud, launched in July, has exceeded management original plans with new customers entering agreements in addition to existing customers who have already licensed the software, committing to the Cloud service. A further positive impact of this performance is on cash flow, as noted above.

 

Sales of the Medics products enjoyed a good year with a number of new customers signing contracts and a high renewal rate of annual subscriptions. Multiyear renewals have been secured with substantially more customers than anticipated demonstrating high levels of customer satisfaction. A further beneficial impact of the multiyear renewals is on cash flow, as noted above.

 

The migration from HealthRoster V9 to V10 continues in line with management plans. Customers that have migrated are located primarily in the UK, along with customers in the USA and Australia.

 

The Defence business had a productive year securing a major contract with Royal Australian Airforce as well as securing a series of important professional services contract extensions.

 

The Maritime business had a successful year securing a new offshore services customer in addition to closing a number of important follow on licence and services contract extensions.

 

Ian Bowles, Chief Executive Officer of Allocate commented: "2012 was a very important year for Allocate. We launched HealthRoster V10, our most important product for many years and we launched the Allocate Cloud, a completely new HealthRoster service that has been extremely well received by our customers and prospects. Sales of our Medics portfolio of applications exceeded management plans and we continued to secure our 100% renewal rate on HealthRoster. Both the Defence and Maritime businesses again performed solidly.

 

"At the same time as delivering revenue in line with expectations we continued our transition to a business with higher recurring and deferred revenues. Although revenue growth has been masked by both a large order in the prior year and the move to higher recurring and deferred revenues, billings and cash show more significant growth and more fairly reflect the true underlying progress that Allocate has achieved this year.

 

"We remain well placed to support the broader healthcare market in general and specifically the NHS in its goals of improving patient care whilst driving improvements in efficiency."

 

Enquiries:

 

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUAVBRONANUAR
Date   Source Headline
20th Nov 20077:01 amRNSChange of Adviser
8th Nov 200710:08 amRNSHolding(s) in Company
7th Nov 20071:34 pmRNSAward of Contract
5th Nov 20073:00 pmRNSDirector/PDMR Shareholding
18th Oct 200712:08 pmRNSRe Contract
27th Sep 20075:18 pmRNSHolding(s) in Company
27th Sep 20073:30 pmRNSAward of contract
20th Sep 20073:15 pmRNSAward of Contract
19th Sep 200711:31 amRNSHolding(s) in Company
19th Sep 20079:02 amRNSDirector/PDMR Shareholding
5th Sep 200710:25 amRNSHolding(s) in Company
23rd Aug 20071:47 pmRNSAward of Contract
17th Aug 200711:59 amRNSHolding(s) in Company
6th Aug 20071:00 pmRNSAward of Contract
31st Jul 20077:01 amRNSDirector/PDMR Shareholding
30th Jul 200712:29 pmRNSCompany Website
30th Jul 20077:00 amRNSFinal Results
1st Jun 20073:13 pmRNSTotal Voting Rights
23rd May 200712:58 pmRNSIssue of Equity
22nd May 20079:11 amRNSCEO Appointment Confirmed
22nd May 20077:01 amRNSAcquisition
2nd May 20078:50 amRNSIssue of Equity
26th Apr 20079:13 amRNSTrading Update
20th Apr 20072:32 pmRNSHolding(s) in Company
19th Apr 20077:00 amRNSDirector/PDMR Shareholding
17th Apr 20079:34 amRNSDirector/PDMR Shareholding
30th Mar 20073:49 pmRNSIssue of Equity
27th Mar 20073:09 pmRNSDirector/PDMR Shareholding
27th Mar 20072:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20075:06 pmRNSHolding(s) in Company
20th Mar 200710:00 amRNSDirectorate Change
13th Mar 20074:28 pmRNSHolding(s) in Company
1st Mar 200712:55 pmRNSHolding(s) in Company
22nd Feb 20079:16 amRNSHolding(s) in Company
22nd Feb 20079:12 amRNSHolding(s) in Company
19th Feb 200712:04 pmRNSDirector/PDMR Shareholding
19th Feb 200712:03 pmRNSHolding(s) in Company
19th Feb 200712:00 pmRNSHolding(s) in Company
16th Feb 20074:28 pmRNSDirector/PDMR Shareholding
15th Feb 20074:41 pmRNSDirector/PDMR Shareholding
15th Feb 20073:03 pmRNSHolding(s) in Company
15th Feb 20077:01 amRNSInterim Results
9th Feb 20073:58 pmRNSIssue of Equity
9th Feb 20079:55 amRNSHolding(s) in Company
17th Jan 20079:15 amRNSBoard Change
19th Dec 200610:15 amRNSTotal Voting Rights
18th Dec 20063:31 pmRNSDirectorate Change & AGM
8th Dec 20069:17 amRNSHolding(s) in Company
7th Dec 20064:13 pmRNSHolding(s) in Company
5th Dec 20067:01 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.